This is an aggregated industry headline. Read the full story at PharmaVoice →
Doctor-turned-dealmaker reveals his M&A playbook
Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.
By PharmaVoice
· Jul 1, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca has impressed oncology patient groups, rising to second place on PatientView's corporate reputatio…
The WeekFierceBiotech ↗
Insilico Medicine has signed a deal worth up to $600 million with Japanese Big Pharma Takeda to collaborate on…
The WeekBriefing
Tzield gains accelerated approval to delay insulin decline in children 8–17 with recently diagnosed Stage 3 ty…